Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors

Neoplasms Clinical Trial

Official title:

A Phase Ia, Multicenter, Open and Dose-increasing Study of DP303c to Evaluate the Safety , Pharmacokinetics, Immunogenicity and Antitumor Activity of Subjects With HER2-Positive Advanced Solid Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04146610
• Other study ID #: DP303c201801
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: November 2019
• Est. completion date: June 2021

Study information

• Verified date: October 2019
• Source: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A phase Ia, multicenter, open and dose-increasing study of DP303c to evaluate the safety , pharmacokinetics, immunogenicity and antitumor activity of subjects with HER2-positive advanced solid tumors.

Description:

Dose escalation study: Primary purpose: To investigate the safety and tolerability of DP303c in subjects with HER2-positive advanced solid tumors . Secondary purpose:1. To characterize the pharmacokinetics(PK) profile of DP303c;2. To assess the preliminary anti tumor activity of DP303c; 3. To characterize immunogenicity of DP303c.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 30
• Est. completion date: June 2021
• Est. primary completion date: June 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Voluntary agreement to provide written informed consent;

• Aged 18 to 75 years, both male and female;

• Patients with advanced solid tumors diagnosed by histology and / or cytology, confirmed to be HER2 positive by pathological examination, unable to accept or have no standard treatment, failure of standard treatment (disease progress or treatment without remission after treatment) or intolerable patients; HER2-positive is defined as IHC 2+ and ISH positive or IHC 3+; IHC scores of breast cancer and gastric cancer are based on their respective standards, while IHC scores of other cancers are based on the scoring standards of breast cancer;

• The ECOG performance status is 0 to 1,and the expected survival time is more than 3 months;

• Subjects must have laboratory values within the limits described below:

ANC =1.5 x 109/L Platelet count =100 x 109/L Hemoglobin =9 g/dL Serum creatinine within normal limits OR creatinine clearance =60 mL/minute Serum total bilirubin =1.5 x ULN (up to 3 x ULN in subjects with Gilbert's syndrome) AST (SGOT) and ALT (SGPT) =2.5 x ULN (OR =5 X ULN for subjects with liver metastases) PT/INR and APTT =1.5 x ULN

• According to the RECIST v1.1 standard, there must be a measurable lesion at the base line;

• WOCBP must have a negative pregnancy test prior to study entry;

• WOCBP and male subjects must agree to use adequate contraception from study entry through at least 12 weeks after the last dose of study drug (see Appendix 5);

• A washout period is required for subjects who have recently received systemic antitumor therapy. The period prior to the subject's planned first dose of DP303c must be either at least 28 days or 5 half-lives, whichever is shorter. Antitumor therapy includes chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy (except local radiotherapy for pain relief, 14 days after treatment).

Exclusion Criteria:

• Pregnant or breastfeeding women;

• Refusal to use effective methods of contraception (see inclusion criteria for details);

• Not recovered from AEs caused by previous drugs or radiotherapy (reference NCI CTCAE 5.0, =Grade 1 or at baseline), with the exception of alopecia;

• History of cardiac dysfunction with LVEF <40% while on trastuzumab therapy;

• Subjects with a history of allergy to any components(tratozumab analogues, MMAE, sodium citrate dihydrate, citrate monohydrate, polysorbitol 20 and sucrose, etc.) of DP303cand those who researchers consider to be more serious;

• A history of central nervous system (CNS) metastases or epilepsy, asymptomatic or stable, and not requiring treatment at least 4 weeks before study therapy began;

• Active lung infection or pneumonitis or a history of non-infectious interstitial lung disease;

• Requires supplemental oxygen;

• History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia. Subjects who have the following types of cardiac impairment at the time of enrollment:

New York Heart Association class III or IV heart disease Uncontrolled angina, congestive heart failure, or myocardial infarction within 6 months prior to enrolment An LVEF by echocardiogram (ECHO) or multi-gated acquisition (MUGA) scan <50% or below the lower limit of normal for the institution QT interval prolongation (>450 ms in males, >470 ms in females),QT interval correction (QTcF) was corrected by Fridericia formula

• In the first 90 daysof the study, Cumulative anthracycline dose =360 mg/m2 doxorubicin or equivalent;

• Peripheral neuropathy =Grade 2 or greater (NCI CTCAE v 5.0);

• 12.Non-manageable electrolyte imbalances including hypokalemia, hypocalcemia, or hypomagnesemia (=Grade 2 or greater based on NCI CTCAE v 5.0);

• Any uncontrollable intercurrent illness, infection, or other conditions that could limit study compliance or interfere with assessments;

• Serologic status reflecting active hepatitis B or C infection;

• Subjects with immunodeficiency, including HIV positive;

• Patients were treated with CYP3A inhibitors within 14 days of the first dose (drugs that increased specific CYP substrate AUC = 5 times, such as Mibefradil, verapamil, diltiazem, nefazodone, clarithromycin, Telithromycin, Troleandomycin, Erythromycin, fluconazole, itraconazole, ketoconazole, Posaconazole,VoriconazoleTablets,Elvitegravir,indinavir,lopinavir, Nelfinavir,Ritonavir,Saquinavir, Boceprevir,Incivo,telaprevir,Conivaptan,idelalisib) or strong CYP3A inducers (Avasimibe, phenobarbital, phenytoin, carbamazepine,Rifampicin, rifabutin,enzalutamide, mitotane, Hypericum perforatum );

• Other serious or uncontrollable diseases or conditions that may affect the assessment of the primary endpoint or that the investigator considers to be at risk for participants participating in this study.

Related Conditions & MeSH terms

• Neoplasms

Intervention

Drug:
• an antibody drug conjugate
Multiple dose grouping

Locations

Country	Name	City	State
China	Fudan University Cancer Hospital	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximal Tolerance Dose (MTD) of Dp303c	The dose level in which >= 2 out of 6 patients have dose-limiting toxicity (DLT). The MTD is defined as the previous dose level.	The first treatment cycle 21 days
Secondary	Maximum concentration (Cmax) of DP303c	The pharmacokinetics(PK) profile of DP303c	approximately 2 years
Secondary	Time of peak plasma concentration (Tmax)	The pharmacokinetics(PK) profile of DP303c	approximately 2 years
Secondary	Area under the plasma concentration time curve (AUC) of DP303c	The pharmacokinetics(PK) profile of DP303c	approximately 2 years
Secondary	Overall response rate (ORR)	To preliminarily evaluate ORR in patients with advanced solid tumors.	approximately 2 years
Secondary	Duration of Response (DoR)	To preliminarily evaluate DoR in patients with advanced solid tumors.	approximately 2 years
Secondary	Immunogenicity (anti-drug antibody ADA)	Percentage of subjects producing detectable anti-drug antibodies (ADA)	approximately 2 years